* Duaklir genuair approved in european union for chronic obstructive pulmonary disease Source text for Eikon: Further company coverage:
the rating agency) LONDON, November 21 (Fitch) Fitch Ratings has downgraded UK-based pharmaceutical AstraZeneca PLC 's ( AstraZeneca ) Long-term Issuer Default Rating (IDR) and senior unsecured rating to 'A+' from 'AA-'. The Outlook
Nov 20 (Reuters) - A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc 's heartburn pill Nexium and Roche's antiviral Valcyte, a court filing showed.
Underlying govt bond over midswaps, equivalent to 63.5 bp
* Says receives order from AstraZeneca of about 2.4 million Swedish crowns
* Investor day comes 8 days before Pfizer can resume pursuit
Nov 18 (Reuters) - AstraZeneca executives, speaking to reporters: * CEO says hard to comment on read-across from Pfizer/Merck cancer
MUMBAI, Nov 18 (Reuters) - Ranbaxy Laboratories Ltd has sued the U.S. Food and Drug Administration (FDA) for revoking approvals granted to the Indian firm to launch copies of two drugs including AstraZeneca Plc 's heartburn pill Nexium, court documents showed.
LONDON, Nov 18 (Reuters) - AstraZeneca shareholder Neil Woodford said on Tuesday his belief in the drugmaker's independent prospects were now "even stronger" as a result of the firm's strong pipeline of new products.
LONDON, Nov 18 (Reuters) - AstraZeneca , determined to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May, said it had made good progress in developing a pipeline of new drugs.